Clinical trial of empagliflozin in the traetment of patients with heart failure after acute myocardial infarction
Objective To observe the clinical efficacy and safety of empagliflozin tablets in the treatment of patients with heart failure after acute myocardial infarction(AMI).Methods The patients with heart failure after AMI were randomly divided into control and treatment groups.The control group was given conventional anti-heart failure treatment.The treatment group was given empagliflozin 10 mg per time,once a day,orally,on the basis of control group.The clinical efficacy,cardiac function indexes,scores of minnesota living with heart failure questionnair(MLHFQ)and safety were compared between the two groups.Results Treatment group were enrolled 56 cases,1 case dropped out,and 55 cases were finally included in the statistical analysis.Control group were enrolled 58 cases,3 cases dropped out,and 55 cases were finally included in the statistical analysis.After treatment,the total effective rates of treatment and control groups were 83.64％(46 cases/55 cases)and 56.36％(31 cases/55 cases)with significant difference(P＜0.05).After treatment,the N-terminal B-type brain natriuretic peptide levels of treatment and control groups were(833.12±112.73)and(1 210.93±98.92)pg·mL-1,the interleukin-6 levels were(6.07±2.25)and(11.06±3.03)ng·L-1,the hypersensitive C-reactive protein levels were(6.82±2.17)and(13.20±3.18)mg·L-1,the 6 min walking distances were(345.15±51.96)and(246.72±57.90)m,the left ventricular ejection fractions were(53.11±5.97)％and(49.65±5.20)％,the MLHFQ scores were(49.38±9.08)and(60.05±10.07)points,respectively.The differences of above indexes were statistically significant between two groups(all P＜0.05).The adverse drug reactions of treatment group were loss of appetite and dizziness,which those in control group were abdominal bloating.The total incidences of treatment and control groups were 5.45％and 1.82％without significant difference(P＞0.05).Conclusion Empagliflozin tablets can significantly improve the clinical efficacy of patients with heart failure after AMI,improve the cardiac function and quality of life,without increasing the incidence of adverse drug reactions.
万方数据
维普
